Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck China CEO Michel Vounatsos And Emerging Markets R&D Senior VP RuiPing Dong On Provincial Management: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Merck & Co. Inc. CEO Kenneth Frazier was the keynote speaker at the China Healthcare Investment Conference in Beijing March 23, stressing that his trip highlighted the place the Chinese market holds for the company's growth. After the conference, Merck, Sharpe and Dohme China President Michel Vounatsos and Merck Research Laboratory Senior VP for Emerging Markets RuiPing Dong spoke with PharmAsia News about navigating China's provincial markets and fitting China into a global R&D strategy.
Advertisement

Related Content

Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
Merck Invests In China Oncology Start-Ip BeiGene
Merck Invests In China Oncology Start-Ip BeiGene
Merck Invests In China Oncology Start-up BeiGene
Merck Invests In China Oncology Start-up BeiGene
Merck Teams Up With Sinopharm On Vaccines As It Gears Up For Gardasil Approval In China
Merck Teams Up With Sinopharm On Vaccines As It Gears Up For Gardasil Approval In China
Merck Expands Manufacturing Site In China As Part Of Its Global Restructuring Program
Asian CROs On The March, But Tie-Ups Carry Risk: Analyst
Advertisement
UsernamePublicRestriction

Register

SC077715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel